(Q53447100)

English

Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.

scientific article published on 15 December 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21159061%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21159061%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21159061%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Ki Cheong Park

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21159061%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Seung Won Kim

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21159061%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Ji Hyun Park

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21159061%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Eun Hye Song

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21159061%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Jeong Won Yang

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21159061%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Hyun Joo Chung

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21159061%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Hye Jin Jung

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21159061%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Ho Jeong Kwon

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21159061%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Seung Hoon Choi

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21159061%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

15 December 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21159061%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21159061%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

102

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21159061%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21159061%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

343-350

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21159061%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Epigenomics and epigenetic therapy of cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Histone deacetylases and cancer: causes and therapies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Histone deacetylase inhibitors: multifunctional anticancer agents.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Erythroleukemic Differentiation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Transcription therapy for cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

The biology of VEGF and its receptors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Cancer without disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Targeting HIF-1 for cancer therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Basement membranes: structure, assembly and role in tumour angiogenesis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Bioisosterism: A Rational Approach in Drug Design

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Rational development of histone deacetylase inhibitors as anticancer agents: a review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Matrix metalloproteinases in tumour invasion and metastasis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Potential applications of tissue inhibitor of metalloproteinase (TIMP) overexpression for cancer gene therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Epigenetic predisposition to expression of TIMP1 from the human inactive X chromosome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Trichostatin A-histone deacetylase inhibitor with clinical therapeutic potential-is also a selective and potent inhibitor of gelatinase A expression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Trichostatin A Induces Morphological Changes and Gelsolin Expression by Inhibiting Histone Deacetylase in Human Carcinoma Cell Lines

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Transcriptional Regulation of the p21(WAF1/CIP1)Gene

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01798.X

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53447100&oldid=1480346634"